Labcorp Holdings LH

Reference table

1. What it is

Labcorp Holdings (NYSE: LH) is a global diagnostics and lab-services company headquartered in Burlington, NC. It is one half of the US clinical-lab duopoly (with Quest Diagnostics) and also runs a biopharma laboratory-services arm (central labs and early-development/CRO work) that serves drug developers. The company legally "commenced operations" on 2024-04-16 as the post-spin holding company after separating its former Fortrea/Covance clinical-trials business; the operating history traces back to the 1990 IPO. Fiscal year ends December 31.

Revenue mix (FY2025, from filings — FMP product segmentation):

• The FMP product tag reports "Labcorp Diagnostics" $10.88B of the $13.95B total; the remainder (~$3.1B) is the Biopharma Laboratory Services segment (Central Labs + Early Development), which the Q1'26 earnings release breaks out separately (Central Labs +11.3%, Early Development +0.6% in Q1'26). Post-Fortrea spin, the large legacy "Covance Drug Development" line has rolled off the segmentation (visible in the 2017–2023 history).
• By geography (historical FMP geo tag): North America dominates (~$13.1B of $16.1B in the last fully-tagged FY2021), with Europe ~$2.1B and other countries ~$1.0B. The revenue base is North-America-concentrated, which ties the top line to US reimbursement policy (Medicare/PAMA lab-fee schedules) — a structural risk, not a growth driver.

The strategy is a diagnostics roll-up: acquire regional and health-system labs, insource hospital lab operations under management agreements, and layer specialty/companion-diagnostics and AI-driven operational efficiency on top. This is a scale-and-consolidation story, not a product-innovation story.

2. The expert thesis — why coverage is essentially absent (traceable)

There is no meaningful expert conviction on Labcorp in the Synthos knowledge base. total_claims = 1, and that single claim is only tangentially related:

• Huberman Lab (huberman_lab-v4HRWgwjP_k:e39dbaf4cf, nominally "bullish", conviction 80, dated 2025-02-20) says: "Regular blood work is vital when modifying sex steroids because hormones operate on exquisite negative-feedback loops that overshooting can disrupt." This is general health advice that happens to mention blood work — it is not a thesis on Labcorp the equity, its valuation, its competitive position, or its cash flows. It would be intellectually dishonest to present this as expert endorsement of the stock.

Honest composite note. Net thesis-relevant conviction is effectively zero. This deep dive is therefore fundamentals- and quant-driven, and the verdict below rests entirely on the numbers, the balance sheet, the valuation, and management's own disclosures — not on any distilled expert panel. When breadth is this thin, we say so plainly and we do not manufacture conviction.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them. All EPS figures are adjusted (non-GAAP) EPS, consistent with how the Street and management guide LH; GAAP diluted EPS was $10.46 in FY25.

Synthos fair value = the base case, ~$300 (+5%), with the full $225–$360 span as the honest range. Our base sits essentially at the Street's $311 consensus and $300 median — we do not see hidden upside the market is missing, nor a glaring mispricing. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). LH is neither an exponential nor even a high-quality compounder — it is a mature, defensive cash cow:

• Forward growth: revenue CAGR FY25→FY30E ~1.8% ($13.95B → $15.22B consensus). Adjusted-EPS CAGR is healthier at ~8% (FY26E $18.01 → FY30E $24.46), but that gap is the tell: per-share growth is manufactured by margin gains and buybacks, not by selling meaningfully more testing.
• Acceleration (the 2nd derivative) is flat-to-negative: consensus revenue actually dips from ~$17.1B FY29E to ~$15.2B FY30E in the FMP set (analyst-count noise across years), and the multi-year trend is low-single-digit with no inflection. There is no GLP-1-style demand shock here.
• Room to run: the US clinical-lab TAM is large but already consolidated into a duopoly, and the growth lever is share-gain/insourcing, not category expansion. At a $23.5B cap the stock could mechanically move, but the business has no exponential runway.
• Reinvestment runway: capex is light (~3% of revenue) and much of the "reinvestment" is bolt-on M&A funded partly with debt — accretive but not compounding at a high ROIC (ROIC ~7.5%).

Exponential Potential: Low (2/10). Own LH — if at all — for defensive ballast, a ~1% dividend, and low-teens forward earnings multiple, not for growth. Per our flagship philosophy we hunt forward next-exponentials; LH is the opposite archetype — a trailing, decelerating compounder — and is disqualified from the flagship growth sleeve on that basis.

5. Financials (real numbers — FMP annual/quarterly)

• Revenue: FY25 $13.95B, +7.2% (FY24 $13.01B, +7.0% on FY23 $12.16B). But note ~half of that reported growth is acquisitions/FX; organic is ~3% (Q1'26 organic +3.1%).
• Quarterly trajectory: Q1'25 $3.35B → Q2 $3.53B → Q3 $3.56B → Q4 $3.52B → Q1'26 $3.54B (+5.8% YoY). Steady, seasonal, no acceleration.
• Margins: gross 27.8% TTM, EBITDA 14.6% TTM, operating ~11%, net 6.7% TTM. Adjusted operating margin ~14.4% (management basis). These are thin, volume-driven lab-services margins — a world away from a branded-pharma or software model.
• Earnings: GAAP net income $876.5M FY25 (EPS diluted $10.46). Adjusted EPS ran ~$17 (Q1'26 adj EPS $4.25, +10.6% YoY). The gap between GAAP $10.46 and adj ~$17 is amortization of acquired intangibles + restructuring — inherent to a roll-up, and a reason to weight adjusted EPS carefully, not blindly.
• Cash flow: operating CF $1.64B, capex −$0.43B, FCF ~$1.21B FY25 (FCF yield ~5.9%). Clean cash conversion; FCF comfortably funds the dividend (~$241M) and buybacks (~$450M).
• Balance sheet: total debt $7.20B, net debt $6.67B, net-debt/EBITDA 3.0× — elevated for a slow grower. Goodwill $6.79B + intangibles $3.60B = $10.39B, ~57% of $18.4B total assets (FMP intangibles/assets 55%). Tangible book value is negative (−$22/sh) — the equity is essentially acquired goodwill. Interest coverage 6.99× is adequate.

6. Valuation — priced in or room?

LH is fairly valued, arguably slightly cheap on adjusted earnings but not on GAAP. Trailing GAAP P/E is 25× (the amortization drag), but on the adjusted numbers the Street and management use, forward P/E is ~16× (FY26E $18.01) → ~15× (FY27E $19.49) → ~12× (FY30E $24.46). EV/EBITDA 14.4× and EV/S 2.1× are middle-of-the-road for a defensive lab operator. The FMP forward PEG of ~3.1× flags that you are not paying up for growth here — because there is little growth to pay for. A reverse read: at $287 the market prices roughly a mid-single-digit revenue / high-single-digit adj-EPS grower — i.e. priced for what it is. Street targets (context): consensus $311, high $334, low $300, median $300 — a tight, unanimous-ish "modestly higher" band with zero sell ratings, which itself signals a low-drama, low-conviction name. Our $300 base is right in that pocket. Not a value trap, not a bargain — fairly priced.

7. Technicals (from the FMP tech block)

• Trend: mildly constructive but stretched. $287 sits above the 50-DMA ($262) and roughly at/just above the 200-DMA ($267) — a recovering, not powerful, uptrend. MACD +5.35 (positive).
• Location: just −1.4% off the 52-week high ($290.93), +18% off the 52-week low ($243) — near the top of its range, shallow max drawdown (−1.4% from peak in the window).
• Momentum: RSI(14) 74 — overbought (>70). This is a stretched-entry warning: the stock has run into its highs and a near-term pullback/consolidation is more likely than an immediate breakout. Not a reason to short, but a reason not to chase.
• Relative strength (the tell): LH +8.6% 12-mo vs SPY +20.6% and QQQ +30.3% — a persistent laggard to both the market and growth. It did outperform on 3-mo only recently (+5.2% vs... SPY +13.7%, still lagging). This is defensive underperformance, exactly what you'd expect from a low-beta cash cow in an up market.
• Read: technicals say fairly-valued and overbought near-term — consistent with the fundamental call. No urgency to buy; a pullback toward the 50-DMA (~$262) would be a lower-risk entry for anyone who wants the defensive exposure.

8. Moat & competitive position

LH's moat is scale and network density in a duopoly, not a patent or a brand: a national logistics/specimen-transport network, an installed base of physician and health-system relationships, insourcing/management agreements with hospital labs, and a data asset for companion diagnostics. This produces durable, defensive revenue — but it is a low-margin, low-growth moat, and it is shared with Quest. The binding external threat is reimbursement policy (Medicare PAMA lab-fee schedule cuts) and payer pressure, which caps pricing power regardless of scale. The Biopharma Laboratory Services arm competes with the CRO majors and is more cyclical (tied to biopharma R&D budgets); Q1'26 book-to-bill 1.04 and backlog $8.64B (+5.6% YoY) are steady but not booming.

Peer set (FMP peers, market cap): Quest Diagnostics $23.9B (the direct comp), Illumina $28.5B, DexCom $27.5B, West Pharmaceutical $25.8B, Waters $24.7B, United Therapeutics $23.6B, Biogen $31.9B, STERIS $21.3B, Incyte $23.3B, Zimmer Biomet $16.9B. Against Quest, LH is comparable in scale and multiple; against the broader tools/diagnostics group it carries lower growth and a lower multiple — appropriately.

9. Management, capital allocation & guidance

• Capital allocation: disciplined and shareholder-friendly but M&A-centric — FY25 deployed ~$582M on acquisitions, ~$450M on buybacks, ~$241M on dividends. The dividend (~$2.88/sh, ~1.0% yield, ~26% payout) is well-covered. The risk is the acquisition treadmill: growth depends on continually buying labs at accretive prices while carrying ~3× leverage.
• Insider activity: routine. CEO Adam Schechter and other officers received equity awards in March 2026 and made modest open-market sales (CEO sold 5,903 sh at $254.50 on 2026-05-11; CLO sold 762 sh at $263.89 on 2026-06-08) — small relative to holdings, consistent with normal diversification, no alarming cluster of discretionary selling.
• Management's own guidance (half-weighted — their own book). From the 2026-04-30 Q1'26 earnings release (SEC 8-K, Item 2.02), management raised full-year 2026 guidance: Enterprise revenue $14.65B–$14.80B (growth ~5.0%–6.1%, +20 bps at midpoint) and Adjusted EPS $17.70–$18.35 ($18.03 midpoint, +$0.13). CEO Schechter cited "double-digit Adjusted EPS growth driven by continued momentum across Diagnostics and Central Laboratory," plus AI/robotics investments (Optum.ai collaboration, MyLabcorp app) and strategic wins (CHOP, Illumina oncology genomics, PathAI). Treat as self-interested but corroborated: the raise is modest and the revenue growth (~5-6% reported, ~3% organic) is consistent with the low-growth thesis above — management's own numbers reinforce, rather than contradict, the Watch call.

10. Catalysts & what to watch

• Next earnings: 2026-07-30 (Q2'26; Street adj EPS $4.79, revenue ~$3.71B). Watch organic Diagnostics volume/price and the full-year adj-EPS guide (any further raise or trim).
• Reimbursement policy: Medicare PAMA / clinical-lab fee-schedule developments — the single biggest external swing factor for the base.
• M&A cadence & integration: deal flow, prices paid, and any goodwill-impairment signals given the $10.4B intangibles base.
• Biopharma segment: book-to-bill (1.04) and backlog conversion — the more cyclical, higher-margin growth lever tied to biopharma R&D spend.
• Buyback pace & leverage: whether net-debt/EBITDA drifts back below ~2.5× or the roll-up keeps it near 3×.

Thesis tripwires (what would change the call): a PAMA cut materially below current fee schedules; a debt-funded acquisition that pushes leverage past ~3.5× without clear accretion; a goodwill impairment; or two quarters of organic Diagnostics volume decline. Conversely, an upgrade to Buy — Tactical would need either a de-rating to ~13× adj EPS (price ~$240s) or a genuine organic-growth reacceleration.

11. Key risks

• Leverage + goodwill (structural): net-debt/EBITDA 3.0× and ~57% of assets in goodwill/intangibles (tangible book negative). A roll-up's Achilles heel — one bad deal or impairment hurts.
• Reimbursement/regulatory: North-America-concentrated revenue tied to Medicare/PBM lab-fee policy; PAMA cuts directly compress a thin-margin business.
• Structurally low growth: ~2-4% organic; per-share growth depends on buybacks and continued accretive M&A — if either falters, the (already modest) upside evaporates.
• Cyclicality in Biopharma: the CRO/central-lab arm is exposed to biopharma R&D budget cycles.
• No expert conviction / thin coverage: the Synthos KB offers no independent thesis support (1 tangential claim); the call rests solely on quant and fundamentals, so there is no diverse-expert cross-check to lean on.

12. Verdict, position sizing & monitoring

Watch. Labcorp is a genuinely good, defensive business — duopoly scale, ~$1.2B FCF, a covered dividend, and a fair-to-slightly-cheap adjusted-earnings multiple. But it is not a buy at $287 for a growth-oriented flagship: revenue grows in the low single digits, per-share growth is buyback-manufactured, leverage is a real ~3×, the balance sheet is mostly goodwill, RSI 74 flags an overbought near-term entry, and our base-case fair value (~$300, +5%) sits right on top of the Street. There is no expert conviction in the KB to tip the scales. You are paid to wait, not to win.

• Sizing: if held for defensive ballast, ~1-3% satellite weight — never a core flagship position. Prefer to add on a pullback toward the 50-DMA (~$262) or into a reimbursement-scare dip, not at 52-week highs.
• Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Upgrade to Buy — Tactical only on a de-rating to ~13× adj EPS or a real organic reacceleration.
• Single biggest risk: the levered roll-up model — an M&A misstep or a reimbursement cut against a goodwill-heavy, ~3×-levered balance sheet.

This verdict is logged as a tracked Synthos call as of 2026-07-03 at $286.98.

Provenance & disclosures

• Traceability: 1 KB claim (breadth 1), and it is only tangentially related (general blood-work advice, huberman_lab-v4HRWgwjP_k:e39dbaf4cf, 2025-02-20) — reconciled to a real claim_id but not treated as a stock thesis. Net thesis-relevant conviction ~0. Fabricated conviction is structurally impossible (claim-ID reconciliation); where coverage is absent, we say so.
• Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · management guidance from the 2026-04-30 SEC 8-K (Item 2.02). Forward figures are analyst consensus / management guidance (FMP + SEC), labeled as estimates. All forward EPS are adjusted (non-GAAP); GAAP diluted EPS was $10.46 in FY25.
• Management caveat: LH management guidance is management's own book, half-weighted by design; here it corroborates (does not inflate) the low-growth read.
• Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
• Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").